


## ビスコジル (坐剤中)

## Bisacogyl (in suppository)

日本薬局方におけるカラム選定条件は、「内標準物質，ビスコジルの順に溶出し，その分離度が2以上あるものを用いる」と定められています．CAPCELL PAK C<sub>18</sub> MGII では，分離度が9.9と良好な分離が得られました．

The Japanese Pharmacopoeia requires a column to elute compounds in the order of the internal standard and bisacogyl, with a resolution value of 2 or greater between the two compounds. CAPCELL PAK C<sub>18</sub> MGII showed a resolution of 9.9.



### [HPLC Conditions]

Column	: CAPCELL PAK C <sub>18</sub> MGII S5 ; 4.6 mm i.d. x 150 mm
Mobile phase	: 10 mmol/L Citric acid / CH <sub>3</sub> CN / CH <sub>3</sub> OH = 2 / 1 / 1
Flow rate	: 1.1 mL/min
Temperature	: R.T.
Detection	: UV 254 nm
Inj. vol.	: 20 μL
Sample dissolved in	: 0.5 mL of ethyl <i>p</i> -hydroxybenzoate solution (30 μg/mL in acetonitrile), 0.5 mL of bisacogyl solution (200 μg/mL in tetrahydrofuran) were mixed together. The solution was diluted to 10 mL in a volumetric flask with the mobile phase. 1 μg/mL = 1 ppm